The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.

Ellen BurgessFlorian M M BaeresGeorge BakrisHeidrun Bosch-TrabergMette GislumStephen C L GoughThomas IdornJack LawsonKenneth W MahaffeyJohannes F E MannHenriette MersebachVlado PerkovicKatherine TuttleRichard Pratley

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023)

FLOW will evaluate the effect of semaglutide on kidney outcomes in participants with CKD and T2D, and is expected to complete in late 2024.

Keyphrases

chronic kidney disease
end stage renal disease
clinical trial
electronic health record
phase iii
machine learning
phase ii
skeletal muscle
weight loss
data analysis